Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Several claims align with label excerpts (indication in CDAD and adult dosing, hypersensitivity description, tablet/oral route and oral administration with/without food). However, multiple important details are either unsupported (e.g., efficacy vs. vancomycin as a “targeted” antibiotic; specific adult side effects/concerns; pregnancy/breastfeeding/kidney-liver disease suitability/monitoring; allergy/contraindication phrasing beyond label) or are incomplete/too general relative to label (drug interaction section lacks specificity beyond P-gp substrate; overdosing/other warnings not addressed).
Category Scores
Accurate Statements
Fidaxomicin is an antibiotic used to treat Clostridioides difficile (C. diff) infection in adults.
Indications and Usage 1.1 (CDAD treatment in adult and pediatric patients ≥6 months).
A typical prescription form is a 200 mg tablet taken by mouth.
Dosage and Administration 2.1 (available as oral 200 mg tablets and administered orally).
Dosing depends on the specific C. diff scenario (first episode vs. recurrence) and the prescriber’s plan.
Supported only in a limited way by the label structure (dose is stated as a fixed regimen for adults/pediatrics). The excerpt does not describe episode-dependent dosing; therefore this statement is not fully supported (see unsupportedStatements).
Common side effects/concerns with fidaxomicin include hypersensitivity/allergic reactions.
Warnings and Precautions 5.1 (acute hypersensitivity reactions including dyspnea, rash, pruritus, angioedema).
Allergic reaction symptoms such as rash, swelling, and trouble breathing warrant prompt medical contact if they occur with fidaxomicin.
Warnings and Precautions 5.1 (dyspnea, rash, angioedema; discontinue and institute appropriate therapy if severe hypersensitivity occurs).
Fidaxomicin use requires caution in people with known drug allergies to fidaxomicin or any tablet components.
Contraindications 4 (contraindicated in patients with known hypersensitivity to fidaxomicin or any other ingredient in DIFICID).
The label strength and route for fidaxomicin 200 mg should be 200 mg and oral tablet, respectively.
Dosage and Administration 2.1 (200 mg tablets; administered orally).
Unsupported Statements
A typical prescription form is a 200 mg tablet taken by mouth.
Label excerpt confirms availability and oral route, but does not state that a “typical prescription form” is specifically a tablet (it also provides granules for oral suspension).
Dosing depends on the specific C. diff scenario (first episode vs. recurrence) and the prescriber’s plan.
Label excerpt provides a fixed recommended adult dosage (200 mg twice daily for 10 days) and pediatric dosing by age/ability; it does not describe episode-dependent (first vs recurrence) dosing.
Fidaxomicin is a targeted antibiotic for C. diff compared with broader options such as vancomycin.
Label excerpt includes comparative efficacy language vs vancomycin (Clinical Studies 14.1) and minimal systemic absorption (12.3), but it does not explicitly describe fidaxomicin as a “targeted antibiotic” compared with “broader options such as vancomycin.”
Common side effects/concerns with fidaxomicin include gastrointestinal symptoms such as nausea, vomiting, or diarrhea.
Label excerpt only states that common adverse reactions are listed in Tables 2 and 3; the specific gastrointestinal examples (nausea/vomiting/diarrhea) are not provided in the supplied excerpts.
Severe diarrhea warrants prompt medical contact if it occurs with fidaxomicin.
Label excerpt provided includes hypersensitivity guidance (5.1) but does not provide patient-contact instructions for diarrhea as an adverse event.
People who are pregnant, breastfeeding, or have significant kidney or liver disease should ask a clinician about suitability and monitoring for fidaxomicin.
Label excerpt includes pregnancy and lactation information, but does not mention kidney/liver disease or provide the specific instruction to “ask about suitability and monitoring” for those conditions. Lactation section excerpt states there is no information on transfer/effects, without a monitoring instruction.
Fidaxomicin can interact with other drugs depending on the other medications being taken.
Label excerpt provides specific interaction information (P-gp substrate; cyclosporine co-administration increases concentrations with no dose adjustment recommended). The general statement is not explicitly supported as written because the excerpt does not describe broad interaction guidance beyond transporter/substrate and cyclosporine.
Contradictions
Important Omissions
Adult dosing details: one 200 mg tablet orally twice daily for 10 days (and that dosing is administered orally with or without food).
Importance:
Moderate
Label warning that DIFICID is only for C. difficile-associated diarrhea and is not expected to be effective for other infections.
Importance:
Moderate
Contraindication wording: patients with known hypersensitivity to fidaxomicin or any other ingredient are contraindicated (the AI used a softer “caution” framing).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several statements are general or unsupported (episode-dependent dosing; GI adverse-event examples; diarrhea-specific action; pregnancy/breastfeeding and kidney/liver disease monitoring; broad interaction framing). While hypersensitivity-related statements broadly match the label’s hypersensitivity content, missing or imprecise dosing and warning-for-use limitations could reduce label fidelity.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Multiple claims are not supported by the supplied label excerpts (GI side-effect examples; diarrhea action guidance; episode-dependent dosing; pregnancy/lactation + kidney/liver monitoring; generalized interaction statement; “targeted antibiotic” comparison language).
Suggested Improvement
Restrict claims to what the label excerpts state: (1) specify adult regimen as 200 mg PO twice daily for 10 days (and oral with/without food); (2) avoid episode-dependent dosing language unless supported; (3) describe hypersensitivity symptoms as listed and follow label action (discontinue and institute appropriate therapy); (4) remove unsupported GI side-effect examples and diarrhea prompt-contact instruction; (5) replace generalized interaction statement with label-supported transporter/substrate and cyclosporine co-administration details; (6) omit kidney/liver disease monitoring wording unless present in the label excerpts.